Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effect of Zinc Suplementation on Serum Hemosystein Level in Hemodialysis Patients

This study has been completed.
Information provided by:
Shiraz University of Medical Sciences Identifier:
First received: April 8, 2010
Last updated: NA
Last verified: January 2009
History: No changes posted
The purpose of this study is to study the effect of zinc supplementation in end stage renal failure on hemocystein level.

Condition Intervention
End Stage Renal Failure
Drug: Zinc Supplement
Drug: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Shiraz University of Medical Sciences:

Primary Outcome Measures:
  • decreased hemocystein level [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Enrollment: 100
Study Start Date: February 2009
Study Completion Date: September 2009
Arms Assigned Interventions
Placebo Comparator: placebo
placebo for 6 weeks
Drug: placebo
placebo daily for 6 weeks
Active Comparator: zinc
zinc sulfate 220 mg per day orally for 6 weeks
Drug: Zinc Supplement
in 50 patients zinc sulfate 220 mg per day orally for 6 weeks

Detailed Description:
hemocystein increased in end stage renal failure and zinc involved in hemocystein metabolism thus zinc supplementation may be effective on hemocystein level.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • hemodialysis for 3 months
  • older than 18 years old
  • serum level of zinc less than 72.6 microgram/ l in men and less than 70 microgram/ l in female

Exclusion Criteria:

  • acute renal failre
  • malabsorption
  • history of steroid or cytotoxic consumption
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01101217

Iran, Islamic Republic of
Shiraz University Hemodialysis Center
Shiraz,, Fars, Iran, Islamic Republic of, 098
Sponsors and Collaborators
Shiraz University of Medical Sciences
  More Information

Responsible Party: Office of Vice Chancellor for research in Shiraz UMS, Shiraz University of Medical Science Identifier: NCT01101217     History of Changes
Other Study ID Numbers: 4542 
Study First Received: April 8, 2010
Last Updated: April 8, 2010
Health Authority: Iran: Ministry of Health

Keywords provided by Shiraz University of Medical Sciences:
hemocystein zinc renal failure

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Failure, Chronic
Renal Insufficiency, Chronic
Kidney Diseases
Urologic Diseases
Trace Elements
Growth Substances
Physiological Effects of Drugs processed this record on October 27, 2016